Literature DB >> 29459631

Biochemical validation of EHMT1 missense mutations in Kleefstra syndrome.

Ayumi Yamada1, Chikako Shimura1, Yoichi Shinkai2.   

Abstract

Kleefstra syndrome (KS) (9q34 deletion syndrome) is a rare autosomal dominant disorder characterized by intellectual disability, frequently coupled with a spectrum of complex physical and clinical manifestations. As the euchromatic histone methyltransferase-1 gene (EHMT1, GLP, or KMT1D) within the 9q34 region is deleted or mutated in most of the individuals with KS, its absence or defect in one allele is speculated to cause the major symptoms of the syndrome. Most of the EHMT1 mutations are frameshift or nonsense mutations, but two individuals with KS were reported to possess EHMT1 missense mutations. These two mutations have been predicted to cause a defective enzymatic function, but precise biochemical validation was not conducted. Therefore, we validated these two mutations by performing in vitro histone methyltransferase (HMT) activity assay and found that C1073Y and R1197W mutations severely affected the HMT activity. Additionally, the same amino-acid substitutions in mouse GLP induced impairment of in vivo GLP function. Furthermore, these two EHMT1 mutants showed defective heterocomplex formation with G9a (partner HMT) which is essential for their in vivo HMT function. Conclusively, our biochemical characterization clearly demonstrates that the previously reported two missense mutations of EHMT1 deteriorate HMT activity and GLP function, which presumably cause KS.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29459631     DOI: 10.1038/s10038-018-0413-3

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  12 in total

1.  Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability.

Authors:  Tjitske Kleefstra; Jamie M Kramer; Kornelia Neveling; Marjolein H Willemsen; Tom S Koemans; Lisenka E L M Vissers; Willemijn Wissink-Lindhout; Michaela Fenckova; Willem M R van den Akker; Nael Nadif Kasri; Willy M Nillesen; Trine Prescott; Robin D Clark; Koenraad Devriendt; Jeroen van Reeuwijk; Arjan P M de Brouwer; Christian Gilissen; Huiqing Zhou; Han G Brunner; Joris A Veltman; Annette Schenck; Hans van Bokhoven
Journal:  Am J Hum Genet       Date:  2012-06-21       Impact factor: 11.025

Review 2.  Regulation and function of H3K9 methylation.

Authors:  Yoichi Shinkai
Journal:  Subcell Biochem       Date:  2007

3.  G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription.

Authors:  Makoto Tachibana; Yasuko Matsumura; Mikiko Fukuda; Hiroshi Kimura; Yoichi Shinkai
Journal:  EMBO J       Date:  2008-09-25       Impact factor: 11.598

Review 4.  H3K9 methyltransferase G9a and the related molecule GLP.

Authors:  Yoichi Shinkai; Makoto Tachibana
Journal:  Genes Dev       Date:  2011-04-15       Impact factor: 11.361

5.  Update on Kleefstra Syndrome.

Authors:  M H Willemsen; A T Vulto-van Silfhout; W M Nillesen; W M Wissink-Lindhout; H van Bokhoven; N Philip; E M Berry-Kravis; U Kini; C M A van Ravenswaaij-Arts; B Delle Chiaie; A M M Innes; G Houge; T Kosonen; K Cremer; M Fannemel; A Stray-Pedersen; W Reardon; J Ignatius; K Lachlan; C Mircher; P T J M Helderman van den Enden; M Mastebroek; P E Cohn-Hokke; H G Yntema; S Drunat; T Kleefstra
Journal:  Mol Syndromol       Date:  2012-01-24

6.  G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis.

Authors:  Makoto Tachibana; Kenji Sugimoto; Masami Nozaki; Jun Ueda; Tsutomu Ohta; Misao Ohki; Mikiko Fukuda; Naoki Takeda; Hiroyuki Niida; Hiroyuki Kato; Yoichi Shinkai
Journal:  Genes Dev       Date:  2002-07-15       Impact factor: 11.361

7.  Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype.

Authors:  T Kleefstra; W A van Zelst-Stams; W M Nillesen; V Cormier-Daire; G Houge; N Foulds; M van Dooren; M H Willemsen; R Pfundt; A Turner; M Wilson; J McGaughran; A Rauch; M Zenker; M P Adam; M Innes; C Davies; A González-Meneses López; R Casalone; A Weber; L A Brueton; A Delicado Navarro; M Palomares Bralo; H Venselaar; S P A Stegmann; H G Yntema; H van Bokhoven; H G Brunner
Journal:  J Med Genet       Date:  2009-03-04       Impact factor: 6.318

Review 8.  Histone modifications for human epigenome analysis.

Authors:  Hiroshi Kimura
Journal:  J Hum Genet       Date:  2013-06-06       Impact factor: 3.172

9.  Selenium-based S-adenosylmethionine analog reveals the mammalian seven-beta-strand methyltransferase METTL10 to be an EF1A1 lysine methyltransferase.

Authors:  Tadahiro Shimazu; Joaquin Barjau; Yoshihiro Sohtome; Mikiko Sodeoka; Yoichi Shinkai
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

10.  Structural biology of human H3K9 methyltransferases.

Authors:  Hong Wu; Jinrong Min; Vladimir V Lunin; Tatiana Antoshenko; Ludmila Dombrovski; Hong Zeng; Abdellah Allali-Hassani; Valérie Campagna-Slater; Masoud Vedadi; Cheryl H Arrowsmith; Alexander N Plotnikov; Matthieu Schapira
Journal:  PLoS One       Date:  2010-01-11       Impact factor: 3.240

View more
  2 in total

1.  Chiari 1 malformation and exome sequencing in 51 trios: the emerging role of rare missense variants in chromatin-remodeling genes.

Authors:  Aldesia Provenzano; Andrea La Barbera; Mirko Scagnet; Angelica Pagliazzi; Giovanna Traficante; Marilena Pantaleo; Lucia Tiberi; Debora Vergani; Nehir Edibe Kurtas; Silvia Guarducci; Sara Bargiacchi; Giulia Forzano; Rosangela Artuso; Viviana Palazzo; Ada Kura; Flavio Giordano; Daniele di Feo; Marzia Mortilla; Claudio De Filippi; Gianluca Mattei; Livia Garavelli; Betti Giusti; Lorenzo Genitori; Orsetta Zuffardi; Sabrina Giglio
Journal:  Hum Genet       Date:  2020-12-18       Impact factor: 4.132

Review 2.  Reprogramming of the epigenome in neurodevelopmental disorders.

Authors:  Khadija D Wilson; Elizabeth G Porter; Benjamin A Garcia
Journal:  Crit Rev Biochem Mol Biol       Date:  2021-10-02       Impact factor: 8.697

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.